Peer review 2008

  1. Azim HA Jr, Peccatori FA, Scarfone G, Acaia B, Rossi P, Cascio R, Goldhirsch A. 2008. Anthracyclines for gestational breast cancer: course and outcome of pregnancy. Ann Oncol 19, no. 8 (August): 1511-1512.
  2. Baenzigen S, Ziegler P, Mazzucchelli L, Bronz L, Speck RF, Manz MG. 2008. Human T cell development and HIV infection in human hemato-lymphoid system mica. Curr Top Microbiol Immunol, no. 324: 125-131.
  3. Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Herrmann R; Central European Cooperative Oncology Group. 2008. Clinical benefit and quality life in patients with advanced pancreatic cancer receiving Gemcitabine plus Capecitabine versus Gemcitabine alone: a multicenter phase III clinical trial SAKK 44/00-CECOG/PAN 1.3.001. J Clin Oncol 26, no. 22 (August): 3695-3701.
  4. Bernhard J, Zahrieh D, Zhang JJ, Martinelli G, Basser R, Hürny C, Forbes JF, Aebi S, Yeo W, Thürlimann B, Green MD, Colleoni M, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Coates AS. 2008. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Br J Cancer 98, no. 1 (January): 25-33.
  5. Berthold DR, Pond G, De Wit R, Eisenberger M, Tannock IF. 2008. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 19, no. 10 (October): 1749-1753.
  6. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock IF. 2008.Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationship between PSA, pain and quality of life response and survival in the TAX-327 study. Clinic Cancer Res 14, no. 9 (May): 2763-2767.
  7. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. 2008. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26, no. 2 (January): 242-245.
  8. Bertoni F. 2008. Hematological Oncology: further ahead. Hematological Oncology 26, no. 1 (March): 1-2.
  9. Bianchi M, Fornasari D, Antonini R, Terziroli B, Nava S, Lang M, Neuenschwander H. 2008. The Pharmacogenetics of Morphine-Induced Analgesia: A Case Report. Journal of Pain and Symptom Management 36, no. 1 (July): e10-12.
  10. Boffi El, Amari E, Toutous-Trellu L, Gayet-Ageron A, Baumann M, Cathomas G, Steffen I, Erb P, Mueller NJ, Furrer H, Cavassini M, Vernazza P, Hirsch HH, Bernasconi E, Hirschel B, Swiss HIV Cohort Study. 2008. Predicting the evolution of kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS 22, no. 9 (May): 1019-1028.
  11. Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V, Trojan A, Helbling D, Pestalozzi B, Caspar C, Ruhstaller T, Roth A, Kappeler A, Dietrich D, Lanz D, Mingrone W, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. 2008. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 19, no.7 (July): 1288.1292.
  12. Borsari A, Bucher B, Brazzola P, Simonetti GD, Dolina M, Bianchetti MG. 2008. Susceptibility of Escherichia coli strains isolated from outpatient children with community-acquired urinary tract infection in Southern Switzerland. Clin Ther 30, no. 11 (November): 2090-2095.
  13. C. Cereda, T. Kuntzer. 2008. The potential use of ephedrine in Lambert-Eaton myasthenic syndrome : clinical and electrophysiological evaluation. Journal of neurology 255, no. 8 (August): 1259-1260.
  14. Cangemi R, Mensah A, Albertini V, Jain A, Mello-Grand M, Chiorino G, Catapano CV, Carbone GM. 2008. Reduced expression and tumor suppression function of the ETS transcription factor ESE-3 in prostate cancer. Oncogene 27, no. 20 (May): 2877-2885.
  15. Cassina T, Mauri R, Engeler A, Giannini O. 2008. Continuous veno-venous hemofiltration with regional citrate anticoagulation: a four-year single-center experience. Int J Artif Organs 31, no. 11 (November): 937-943.
  16. Cavalli F. 2008. The World Cancer Declaration: a roadmap for change. Lancet Oncol 9, no. 9 (September): 810-811.
  17. Ceriani L, Giovanella L. 2008. Simultaneous imaging of pericardial thymoma and parathyroid adenoma by sestamibi scan. Clin Nucl Med 33, no. 8 (August): 542-544.
  18. Ceriani L, Giovanella L. 2008. Symptomatic sternal metastasis mimicking cardiac angina discovered by Tc-99m sestamibi myocardial perfusion scintigraphy. Tumori 94, no. 3 (June): 437-439.
  19. Colleoni M, Viale G, Zahrieh D, Bottiglieri L, Gelber RD, Veronesi P, Balduzzi A, Torrisi R, Luini A, Intra M, Dellapasqua S, Cardillo A, Ghisini R, Peruzzotti G, Goldhirsch A. 2008. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol 19, no. 3 (March): 465-472.
  20. Cresta S, Sessa C, Catapano C, Gallerani E, Passalacqua D, Rinaldi A, Bertoni F, Viganò L, Maur M, Capri G, Maccioni E, Tosi D, Gianni L. 2008. Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer 44, no. 13 (September): 1829-1834.
  21. Crivellari D, Sun Z, Coates AS, Price KN, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Parideans RJ, Castiglioni-Gertsch M, Gelber RD, Colleoni M, Làng I, Del Mastro L, Gladieff L, Rabaglio M, Smith IE, Chirhwin JH, Goldhirsch A. 2008. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 26, no. 12 (April): 1972-1979.
  22. Curigliano G, Spitaleri G, Fingert HJ, De Braud F, Sessa C, Loh E, Cipolla C, De Pas T, Goldhirsch A, Shah R. 2008. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer 44, no. 4 (March): 494-500.
  23. D’Alessandro C, Dellapascuqa S, Orlando L, Santoro L, Maisonneuve P, Torrisi R, Balduzzi A, Scarano E, Ghisini R, Peruzzotti G, Goldhirsch A, Colleoni M. 2008. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy. Breast 14, no. 5 (September-October): 435-441.
  24. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Goldhirsch A, Rocca A, Pietri E, Colleoni MA. 2008. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26, no. 30 (October): 4899-4905.
  25. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P. 2008.Wild-type BRAF is required for response to Panitumumab or Cetuximab in metastatic colorectal cancer. J Clin Oncol 26, no. 35 (December): 5705-5712.
  26. Doolittle ND, Abrey LE, Schenkier TN, Tali S, Bromberg JE, Neuwelt EA, Ossain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E. 2008. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS-Lymphoma Collaborative Group report. Blood 111, no. 3 (February): 1085-1093.
  27. Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, Goldhirsch A, Gray R, Peto R, Pritchard KI, Wood WC, Early Breast Cancer Trialists’ Collaborative Group. 2008. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 371, no. 9606 (January): 29-40.
  28. Felber Diedrich D, Gemperli A, Gaspoz JM, Schindler C, Liu S, Gold D, Schwartz J, Rochat T, Barthélémy JC, Pons M, Roche F, Probst Hensch N, Bridevaux P, Gerbase M,. Neu U, Ackermann-Liebrich U, SAPALDIA team. 2008. Differences in heart rate variability associated with long-term exposure to NO2. Environmental Health Perspectives 110, no. 16 (October): 1357-1361.
  29. Ferreri AJ, Dognini GP, Bairey O, Szomor A, Montalbán C, Horvath B, Demeter J, Uziel L, Soffietti R, Seymour JF, Ambrosetti A, Willemze R, Martelli M, Rossi G, Candoni A, De Renzo A, Doglioni C, Zucca E, Cavalli F, Ponzoni M, International Extranodal Lymphoma Study Group. 2008. The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma. Br J Haematol 143, no. 2 (October ): 253-257.
  30. Ferreri AJ, Dognini GP, Govi S, Crocchiolo R, Bouzani M, Bollinger CR, D'Incan M, Delaporte E, Hamadani M, Jardin F, Martusewicz-Boros M, Montanari M, Szomor A, Zucca E, Cavalli F, Ponzoni M. 2008. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? J Clin Oncol 26, no. 31 (November): 5134-5136.
  31. Ferreri AJM, DolcettI R, Du M-Q, Doglioni C, Rest AG, Politi LS, De Conciliis C, Radford J, Bertoni F, Zucca E, Cavalli F & Ponzoni M. 2008. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. Ann Oncol 19, no. 5 (May): 835-846.
  32. Fiore E, Bernasconi M, Simonetti GD, Rizzi M, Bianchetti MG. 2008. Kidney disease in acute hemorrhagic edema of young children. Turk J Pediatr 50, no. 5 (September-October): 512.
  33. Fiore E, Rizzi M, Ragazzi M, Vanoni F, Bernasconi M, Bianchetti MG, Simonetti GD. 2008. Acute hemorrhagic edema of young children (cockade purpura and edema): a case series and systematic review. J Am Acad Dermatol 59, no. 4 (October): 684-695.
  34. Fischler M, Speich R, Dorschner L, Nicod L, Domenighetti G, Tamm M, Rochat T, Aubert J-D, Ulrich S. 2008.Pulmonary hypertension in Switzerland: treatment and clinical course. Swiss Med Wkly 138, no. 25-26 (June): 371-378.
  35. Forconi F, Poretti G, Kwee I, Sozzi E, Rossi D, Rancoita PMV, Capello D, Rinaldi A, Zucca E, Raspadori D, Spina V, Lauria F, Gaidano G, Bertoni F. 2008. High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. British Journal Haematology 141, no. 5 (May): 622-630.
  36. Forconi F, Rinaldi A, Kwee I, Sozzi E, Raspadori D, Rancoita PMV, Scandurra M, Rossi D, Deambrogi C, Capello D, Zucca E, Marconi D, Bomben R, Gattei V, Lauria F, Gaidano G, Bertoni F. 2008. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. British Journal Haematology 143, no. 4 (November): 532-536.
  37. Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjöld B, Lang I, Jakesz R, Vorobiof D, Gutiérrez J, Van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Piccart-Gebhart M, BIG 02-98 Collaborative Group. 2008. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 100, no. 2 (January): 121-133.
  38. Furlan D, Sahnane N, Carnevali I, Cerutti R, Bertoni F, Kwee I, Uccella S, Bertolini V, Chiaravalli AM, Capella C. 2008. Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. Human Pathol 39, no. 10 (October): 1483-1494.
  39. Fux Ch, Rauch A, Simcock M, Bucher HC, Hirschel B, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Elzi L, Furrer H, Swiss HIV Cohort Study. 2008. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antiviral Therapy 13 (8): 1077-1082
  40. Gianni L, Cole BF, Panzini I, Snyder R, Holmberg SB, Byrne M, Crivellari D, Colleoni MA, Aebi S, Simoncini E, Pagani O, Castiglione-Gertsch M, Price KN, Goldhirsch A, Coates AS, Ravaioli A. 2008. Anemia during adjuvant non-taxane chemotherapy for early breast cancer: incidence and risk factors from two trials of the International Breast Cancer Study Group. Support Care Cancer 16, no. 1 (January): 67-74.
  41. Giovanella L. 2008. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 112, no. 1 (January): 220.
  42. Giovanella L. 2008. Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clin Chem Lab Med 46 (8): 1067-1073.
  43. Giovanella L, Ceriani L, Ghelfo A. 2008. Second-generation thyrotropin receptor antibodies assay and quantitative thyroid scintigraphy in autoimmune hyperthyroidism. Horm Metab Res 40, no. 7 (July): 484-486.
  44. Giovanella L, Ceriani L, Ghelfo A, Maffioli M. 2008. Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland. Int J Biol Markers 29, no. 1 (January-March): 54-57.
  45. Giovanella L, Ceriani L, Suriano S, Ghelfo A, Maffioli M. 2008. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 69, no. 4 (October): 659-663.
  46. Giovanella L, Crippa S, Ceriani L. 2008. Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers. Int J Biol Markers 23, no. 2 (April-June): 129-131.
  47. Giovanella L, Dorizzi RM, Keller F. 2008. A hypothyroid patient with increased free thyroid hormones. Clin Chem Lab Med 46 (11): 1650-1651.
  48. Giovanella L, Pedrazzi P, Jandus P, Marone C. 2008. Steroid responsive encephalopathy associated with autoimmune thyroiditis (SREAT) with negative thyroperoxidase antibodies. Eur J Clin Invest 38, no. 9 (September): 693-694.
  49. Giovanella L, Suriano S, Ceriani L. 2008. Graves' disease, thymus enlargement, and hypercalcemia. N Engl J Med 358, no. 10 (March): 1078-1079.
  50. Giovanella L, Taborelli M, Ceriani L, Zucca E, Cavalli F, Delaloye AB. 2008. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS. Nucl Med Commun 29, no. 6 (June): 535-541.
  51. Glass TR, De Geest S, Hirschel B, Battegay M, Furrer H, Cavassini M, Vernazza PL, Bernasconi E, Rickenbach M, Weber R, Bucher HC, Swiss HIV Cohort Study. 2008. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antiviral Therapy 13 (1): 77-85.
  52. Granziera C, Pollo C, Russmann H, Städler C, Burkhardt JP, Ghika J, Villemure JG, Vingerhoets FJG. 2008. Sub-acute delayed failure of subthalamic DBS in Parkinson disease: the role of micro-lesion effect. Parkinsonism Relat Disord 14 (2): 109-113.
  53. Granziera C, Kuntzer T, Vingerhoets F, Cereda C. 2008. Small cortical stroke in the hand knob mimics anterior interosseus syndrome. Journal of neurology 255, no. 9 (September): 1423-1424.
  54. Gruber G, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Thürlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Price KN, Goldhirsch A, Viale G, Gusterson BA, IBCSG. 2008. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Ann Oncol 19, no.8 (August): 1393-1401.
  55. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W, Herrmann R. 2008. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet oncol 9, no. 2 (February): 132-138.
  56. Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D, Caspar CB, Mingrone W, Beretta K, Strasser F, Ruhstaller T, Mora O, Herrmann R; Swiss Group for Clinical Cancer Research. 2008. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 26, no. 22 (August): 3702-3708.
  57. Lozza L, Rivino L, Guarda G, Joarrossay D, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A, Geginat J. 2008.The strength of T-cell stimulation determines IL-7 responsiveness, secondary expansion and lineage commitment of primed human CD4+IL-7Rhi T cells. Eur J Immunol 38, no. 1 (January): 30-39.
  58. Lübbeke A, Moors KG, Garavaglia G, Hoffmeyer P. 2008. Outcome of obese and nonobese patients undergoing revision total hip arthroplasty. Artritis Rheum 59, no. 5 (May): 738-745.
  59. Moccia A, Ghielmini M. 2008. Monoclonal antibodies for the treatment of hematologic malignancies: schedule and maintenance therapy. Semin Hematol 45, no. 2 (April): 75-84.
  60. Montagna E, Bagnardi V, Rotmensz N, Rodriguez J, Veronesi P, Luini A, Intra M, Scarano E, Cardillo A, Torrisi R, Viale G, Goldhirsch A, Colleoni M. 2008. Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer. Br J Cancer 98, no. 11 (June): 1745-1752.
  61. Mishra N, Cereda C, Carota A. 2008.Lifetime Basilar Migraine: a pontine syndrome? Headache 48, no. 3 (March): 476-478.
  62. Nicolini G, Fogliata A, Vanetti E, Clivio A, Vetterli D, Cozzi L. 2008. Testing the GLAaS algorithm for dose measurements on an amorphous silicon portal imager on low and high energy photon beams. Med Phys 35, no. 2 (February): 464-472.
  63. Nolé F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, Medici M, Adamoli L, Rotmensaz N, Goldhirsch A, Sandri MT. 2008. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 19, no. 5 (May): 891-897.
  64. Oehler-Jänne C, Huguet F, Provencher S, Seifert B, Negretti L, Riener MO, Bonet M, Allal AS, Ciernik IF. 2008. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 26, no. 15 (May): 2550-2557.
  65. Oehler-Jänne C, Taverna C, Stanek N, Negretti L, Lütolf UM, Ciernik IF. 2008. Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: a case-control study. Hematol Onc 26, no. 2 (June): 82-90.
  66. Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M. 2008. Topoisomerase II alpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Breast 17, no. 5 (October): 506-511.
  67. Parati G, Malfatto G, Boarin S, Branzi G, Caldara G, Giglio A, Bilo G, Ongaro G, Alter A, Gavish B, Mancia G. 2008. Device-Guided Paced Breathing in the Home Setting. Circ Heart Fail 1, no. 3 (September): 178-183.
  68. Pentenero M, Cistaro A, Brusa M, Ferraris MM, Pezzuto C, Carnino R, Colombini E, Valentini MC, Giovanella L, Spriano G, Gandolfo S. 2008. Accuracy of 18F-FDG-PET/CT for staging of oral squamous cell carcinoma. Head Neck 30, no. 11 (November): 1488-1496.
  69. Perren A, Cerutti B, Lepori M, Senn V, Capelli B, Duchini F, Domenighetti G. 2008. Influence of Steroids on Procalcitonin and C-reactive Protein in Patients with COPD and Community-acquired pneumonia. Infection 36, no. 2 (March): 163-166.
  70. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindther J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglioni-Gertsch M, Coates AS, Goldhirsch A. 2008. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 26, no. 18 (June): 3006-3014.
  71. Ponti G, Ponzoni M, Ferreri AJ, Foppoli M, Mazzucchelli L, Zucca E. 2008. The impact of histopathologic diagnosis on the proper management of testis neoplasms. Nat Clin Pract Oncol 5, no. 10 (October): 619-622.
  72. Pruneri G, Alietti A, Agnelli L, Morabito F, Laszlo D, Calabrese L, Fabris S, Bertolini F, Agazzi A, Bottiglieri L, Raviele PR, Baldini L, Pileri S, Sabattini E, Bosari S, Maisonneuve P, Lambertenghi-Deliliers G, Bertoni F, Martinelli G, Viale G, Neri A. 2008. Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. Leuk Res 32, no. 10 (October): 1628-1632.
  73. Ragazzi M, Milani G, Edefonti A, Burdick L, Bianchetti MG, Fossali EF. 2008. Left renal vein entrapment: a frequent feature in children with postural proteinuria. Pediatr Nephrol 23, no. 10 (October): 1837-1839.
  74. Ramelli GP, Boscherini D, Kehrli Prilliet B. 2008. Spontaneous spinal epidural hematomas in children: can we prevent a negative prognosis? Reflections on 2 cases. J Child Neurol 23, no. 5 (May): 564-567.
  75. Ramelli GP, Silacci C, Ferrarini A, Cattaneo C, Visconti P, Pescia G. 2008. Microduplication 22q11.2 in a child with autism spectrum disorder: clinical and genetic study. Dev Med Child Neurol 50, no. 12 (December): 953-955.
  76. Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropqaqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G, BIG 1-98 Collaborative and International Breast Cancer Study Groups. 2008. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 9, no. 1 (January): 23-28.
  77. Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A, Coates A, Price KN, Gusterson BA, Viale G, IBCSG. 2008. p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Ann Oncol 19, no. 4 (April): 660-668.
  78. Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Felming GF, Price KN, Thürlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD for the SOFT/TEXT/PERCHE Steering Committee, IBCSG. 2008. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol 19, no. 7 (July): 1231-1241.
  79. Ribeiro RC, Steliarova-Foucher E, Magrath I, Lemerle J, Eden T, Forget C, Mortara I, Tabah-Fisch I, Divino JJ, Miklavec T, Howard S and Cavalli F. 2008. Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study. Lancet Oncol 9, no. 8 (August): 721-729.
  80. Riechelmann RP, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, Knox J. 2008. Sorafenib for merastatic renal cancer: the Pricess Margaret experience. Am J Clin Oncol 31, no. 2 (April): 182-187.
  81. Rocca A, Viale G, Gelber RD, Bottiglieri L, Gelber S, Pruneri G, Ghisini R, Balduzzi A, Petri E, D'Alessandro C, Goldhirsch A, Colleoni M. 2008. Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. Cancer Chemother Pharmacol 61, no. 6 (May): 965-971.
  82. Rodriguez-Abreu D, Filho VB, Zucca E. 2008. Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review. Hematol Oncol 26, no. 1 (March): 8-20.
  83. Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, Pruneri G, Yuen K, Roos D, Lennard A, Devizzi L, Crabb S, Hossfeld D, Pratt G, Dell'Olio M, Choo SP, Bociek RG, Radford J, Lade S, Gianni AM, Zucca E, Cavalli F, Seymour JF, International Extranodal Lymphoma Study Group. 2008. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 19, no. 2 (February): 233-241.
  84. Saletti P, Sessa C, Cavalli F. 2008. 25 or 50 years later? J Clin Oncol 26, no. 30 (October): 4854-4855.
  85. Sanna G, Preda L, Bruschini R, Cossu Rocca M, Verri E, Bellomi M, Goldhirsch A, Nole F. 2008. The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates. Acta Oncol 47 (3): 476-478.
  86. Sessa C, Guibal A, Del Conte G, Ruegg C. 2008. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 5, no. 7 (July): 378-391.
  87. Siano M, Lerch E, Negretti L, Zucca E, Oberson M, Sessa C, Gallino A, Ghielmini M. 2008. A Phase I-II Study to determine the maximum tollerate infusion rate of Ritucimab with special emphasis on monitoring the effect of rituximab on cardiac function. Clin Cancer Res 14, no. 23 (December): 7935-7939.
  88. Sieber R. 2008. 199: Triage process in Swiss Emergency Departments. Annals of Emergency Medicine 51, no.4 (April): 531.
  89. Soldini D, Mora O, Cavalli F, Zucca E, Mazzucchelli L. 2008. Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy-type T-cell lymphoma. Br J Haematol 142, no. 3 (July): 484-486.
  90. Soldini D, Moreno E, Martin V, Gratwohl A, Marone C, Mazzucchelli L. 2008. BM-derived cells randomly contribute to neoplastic and non-neoplastic epithelial tissues at low rates. Bone Marrow Transplant 42, no. 11 (December): 749-755.
  91. Thi Tuyet Nhung VO, Ledergerber B, Keiser O, Hirschel B, Furrer H, Battegay M, Cavassini M, Bernasconi E, Vernazza P, Weber, Swiss HIV Cohort Study. 2008. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 197, no. 12 (June): 1685-1694.
  92. Torrisi R, Bagnardi V, Cardillo A, Bertolini F, Scarano E, Orlando L, Mancuso P, Luini A, Calleri A, Viale G, Goldhirsch A, Colleoni M. 2008. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 99, no. 10 (November): 1564-1571.
  93. Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, Giovanardi F, Veronesi P, Luini A, Orlando L, Viale G, Goldhirsch A, Colleoni M. 2008. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 62, no. 4 (September): 667-672.
  94. Torrisi R, Dellapasqua S, Ghisini R, Viale G, Veronesi P, Luini A, Intra M, Peruzzotti G, Rocca A, Balduzzi A, Cardillo A, Goldhirsch A, Colleoni M. 2008. Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors. Breast 17, no. 6 (December): 654-660.
  95. Untch M, Jackisch C, Procter M, Baselga, J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, De Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkurs-Konefka E, Price C, Haslbauer F, Sahui TS, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A: Hera Study Team. 2008. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 19, no. 6 (June): 1090-1096.
  96. Rey V, Cereda C, Michel P. 2008. Neurological picture. Recurrent asystolia in right middle cerebral artery infarct with predominant insular involvement. Journal of neurology, neurosurgery and psychiatry (JNNP) 79, no. 6 (June): 618.
  97. Van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E. 2008. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma 49 Suppl. 1: 52-58.
  98. Vernazza P, Hirschel B, Bernasconi E, Flepp M. 2008. HIV transmission under highly active antiretroviral therapy. Lancet 372, no. 9652 (November): 1806-1807.
  99. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A, Breast International Group Trial 1-98. 2008. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26, no. 34 (December): 5569-5575.
  100. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Öhlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A. 2008. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from Breast International Group trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26, no. 34 (December): 5569-5575.
  101. Viale G, Regan MM, Maoirano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovàcs A, Pillay K, Öhlschlegel C, Brayw S, Grigolato P, Rusca T, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS, International Breast Cancer Study Group. 2008. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors. J Clin Oncol 26, no. 9 (March): 1404-1410.
  102. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pikkay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch, Coates AS, International Breast Cancer Study Group. 2008. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100, no. 3 (February): 207-212.
  103. Vitolo U, Ferreri AJ, Zucca E. 2008. Primary testicular lymphoma. Crit Rev Oncol Hematol 65, no. 2 (February): 183-189.
  104. Wannesson L, Zucca E. 2008. Who should receive myeloablative therapy for diffuse large B-cell lymphoma? Nat Clin Pract Oncol 5, no. 8 (August): 442-443.
  105. Wolbers M, Bucher HC, Furrer H, Rickenbach M, Cavassini M, Weber R, Schmid P, Bernasconi E, Hirschel B, Battegay M, Swiss HIV Cohort Study. 2008. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Medicine 9, no. 6 (July): 397-405.
  106. Young J, Glass TR, Bernasconi E, Rickenbach M, Furrer H, Hirschel B, Tarr P, Vernazza P, Battegay M, Bucher HC, Swiss HIV Cohort Study. 2008. Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. J Clin Epidemiol 62, no. 6 (June): 632-641.
  107. Zatloukal P, Gervais R, Vansteenkiste J, Bosquee L, Sessa C, Brain E, Dansin E, Urban T, Dohollou N, Besenval M, Quoix E. 2008. Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. J Thorac Oncol 3, no. 8 (August): 894-901.
  108. Zucca E, Bertoni F, Stathis A, Cavalli F. 2008. Marginal zone lymphomas. Hematol Oncol Clin North Am 22, no. 5 (October): 883-901.
  109. Zucca E, Dreyling M, ESMO Guidelines Working Group. 2008. Gastric marginal zone lymphoma of MALT type: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 Suppl. 2 (May): ii70-71.
  110. Zucca E. 2008. Extranodal lymphoma: a reappraisal. Ann Oncol 19 Suppl. 4 (June): iv77-80.